Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
J Contin Educ Nurs ; 52(11): 505-510, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1497419


Health care providers are challenged to meet the simultaneous demands of delivering clinical care and acquiring new information, especially in the context of the coronavirus disease 2019 pandemic, the opioid epidemic, and concurrent escalation in alcohol and other drug use. To address the gap in knowledge related to substance use, screening, brief intervention, and referral to treatment (SBIRT), a self-paced online educational program, was developed and delivered to 169 learners. Posttest knowledge scores increased for all learners and did not differ based on their pace of completion. Results indicated that this module provides a means for busy clinicians to increase their ability to manage substance use, even if their learning occurs in multiple sessions interrupted by other pressing demands. Future iterations of this course could further enhance clinical competency by addition of an online clinical simulation component. [J Contin Educ Nurs. 2021;52(11):505-510.].

COVID-19 , Substance-Related Disorders , Clinical Competence , Humans , Mass Screening , Referral and Consultation , SARS-CoV-2 , Substance-Related Disorders/diagnosis
Subst Abus ; 41(2): 147-149, 2020.
Article in English | MEDLINE | ID: covidwho-104139


We highlight the critical roles that pharmacists have related to sustaining and advancing the changes being made in the face of the current COVID-19 pandemic to ensure that patients have more seamless and less complex access to treatment. Discussed herein is how the current COVID-19 pandemic is impacting persons with substance use disorders, barriers that persist, and the opportunities that arise as regulations around treatments for this population are eased.

Continuity of Patient Care , Coronavirus Infections/complications , Opioid-Related Disorders/complications , Opioid-Related Disorders/therapy , Opioid-Related Disorders/virology , Pneumonia, Viral/complications , Betacoronavirus , Buprenorphine/therapeutic use , COVID-19 , Continuity of Patient Care/legislation & jurisprudence , Humans , Methadone/therapeutic use , Pandemics , Pharmacists , SARS-CoV-2 , United States